Option Care Health (NASDAQ:OPCH) Upgraded at UBS Group

Option Care Health (NASDAQ:OPCH - Get Free Report) was upgraded by equities research analysts at UBS Group from a "neutral" rating to a "buy" rating in a research note issued on Wednesday,Finviz reports. The brokerage presently has a $40.00 target price on the stock. UBS Group's target price indicates a potential upside of 30.34% from the stock's previous close.

A number of other analysts also recently commented on the stock. JPMorgan Chase & Co. increased their price objective on shares of Option Care Health from $40.00 to $41.00 and gave the company an "overweight" rating in a report on Thursday, March 6th. Jefferies Financial Group upgraded Option Care Health from a "hold" rating to a "buy" rating and lifted their price objective for the stock from $26.00 to $35.00 in a research report on Thursday, January 23rd. JMP Securities restated a "market outperform" rating and issued a $36.00 target price on shares of Option Care Health in a report on Tuesday, April 22nd. Bank of America raised Option Care Health from a "neutral" rating to a "buy" rating and raised their target price for the stock from $26.00 to $33.00 in a research note on Monday, January 13th. Finally, Barrington Research reissued an "outperform" rating and set a $38.00 price target on shares of Option Care Health in a research report on Monday, April 21st. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $35.50.

Option Care Health Trading Down 6.9 %

Shares of OPCH opened at $30.69 on Wednesday. Option Care Health has a 52-week low of $21.39 and a 52-week high of $35.53. The stock has a market cap of $5.04 billion, a PE ratio of 25.79, a price-to-earnings-growth ratio of 2.30 and a beta of 1.07. The firm's fifty day moving average is $33.34 and its two-hundred day moving average is $28.79. The company has a quick ratio of 1.32, a current ratio of 1.73 and a debt-to-equity ratio of 0.77.

Insider Activity at Option Care Health

In other Option Care Health news, insider Michael Bavaro sold 30,996 shares of Option Care Health stock in a transaction dated Friday, February 28th. The shares were sold at an average price of $33.26, for a total transaction of $1,030,926.96. Following the completion of the sale, the insider now directly owns 44,974 shares in the company, valued at $1,495,835.24. This trade represents a 40.80 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.64% of the stock is owned by insiders.

Hedge Funds Weigh In On Option Care Health

Several large investors have recently made changes to their positions in OPCH. JPMorgan Chase & Co. lifted its stake in Option Care Health by 29.6% during the fourth quarter. JPMorgan Chase & Co. now owns 1,511,403 shares of the company's stock worth $35,065,000 after purchasing an additional 344,875 shares in the last quarter. Graypoint LLC purchased a new stake in shares of Option Care Health in the 4th quarter valued at $1,161,000. Charles Schwab Investment Management Inc. lifted its stake in Option Care Health by 6.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,510,131 shares of the company's stock worth $58,235,000 after acquiring an additional 147,054 shares in the last quarter. Global Alpha Capital Management Ltd. boosted its holdings in Option Care Health by 38.1% during the 4th quarter. Global Alpha Capital Management Ltd. now owns 68,810 shares of the company's stock valued at $1,596,000 after acquiring an additional 18,992 shares during the period. Finally, Y Intercept Hong Kong Ltd acquired a new position in Option Care Health in the 4th quarter valued at about $327,000. 98.05% of the stock is currently owned by institutional investors and hedge funds.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.